Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Cisplatin vs. Carboplatin in Small Cell Lung Cancer
Author
Howard (Jack) West, MD

I recently received a question on the Q&A Forum about the use of cisplatin vs. carboplatin in SCLC. In contrast to the smoldering debate about cisplatin vs. carboplatin in NSCLC that I described in a recent post, there's been very little study and not as much debate about SCLC. What little I can say is that there was a trial published in 1994 by Skarlos and colleagues from Greece that randomized patients to cisplatin or carboplatin with etoposide, and it included patients with both limited and extensive SCLC (abstract here):

Skarlos SCLC cis vs carbo schema (Click to enlarge)

This trial is so old that the carboplatin dose is in mg/m2, which is an older way of dosing this agent than our current one that uses age, patient sex, and kidney function to calculate a drug exposure known as area under the curve, or AUC. Our current dosing of carboplatin is almost always by AUC. And just FYI, the dose of etoposide listed on my figure is different from the one listed in the abstract. I believe the latter is a typo/misprint, but I don't have the original paper availabel to double check that. The dose of 300 mg/m2 would be a staggeringly high dose, at least if we're talking IV and not oral etoposide.

The study demonstrated relarkably similar results for the two arms, with very impressive complete response rates of 57% and 58% and median survivals of 12.5 and 11.8 months for cisplatin and carboplatin, respectively. The toxicity profile favored carboplatin, with significantly lower rates of severe nausea/vomiting, neurotoxicity (neuropathy), and leukopenia (low white blood cell counts), and infections in the patients who received carboplatin. So this work suggests comparable results and perhaps a more favorable therapeutic index (balance of activity vs. side effects) for carboplatin.

That's one reason I modestly favor carboplatin over cisplatin outside of a clinical trial in ED-SCLC. Many additional trials have been done with carboplatin-based chemo in ED-SCLC that show survival about what you'd expect for cisplatin as well, and I'll soon give some additional information on one trial presented at ASCO 2007 that compared two carboplatin-based doublet regimens.

However, in a curative setting like LD-SCLC, I still favor cisplatin. There are no places in oncology where cure rates are better with carboplatin than cisplatin, but there are a number where cisplatin is signficantly (if modestly) better than carboplatin. In fact, the full paper showed some trends that looked a little worse for carboplatin recipients LD-SCLC, but the trial is small, and the differences weren't enough to be statistically significant. Given the high stakes and the much more extensive body of evidence with cisplatin in LD-SCLC (the best data we have in long-term cure rates in LD-SCLC are with cisplatin/etoposide and twice daily RT, as described in a prior post), that's my standard approach unless there's a reason a patient can't tolerate cisplatin. At least we have some evidence to suggest that patients who get carboplatin instead of cisplatin aren't compromising significantly and may do just as well, based on this limited Greek experience.

Next Previous link

Previous PostNext Post

Related Content

Image
Trial data ASCO 2024
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO. To watch the complete playlist, click here.         
Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Recent Comments

JOIN THE CONVERSATION
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on
EGFR
By happybluesun on